Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on November 4, 2019, to report the closing of a previously announced underwritten public offering. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing reports a capital raise event rather than operational financial results. The company sold 3,529,412 shares of common stock at a public offering price of $0.85 per share. The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital resulting from the closing of the public offering on November 4, 2019.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the offering closure.
Investor Verification Checklist
- Verify the total gross proceeds from the offering (3,529,412 shares at $0.85 per share).
- Confirm the updated number of outstanding shares post-offering.
- Review the company's most recent 10-Q or 10-K for current cash balances and burn rate, as this 8-K does not provide liquidity data.
- Check for any underwriting discounts or commissions that may reduce net proceeds.